For patients with moderate-to-severe renal dysfunction, the bone modifying agent ...

For patients with moderate-to-severe renal dysfunction, the bone modifying agent of choice is

A. Pamidronate

B. Zoledronic acid

C. Denosumab

D. Calcium carbonate

Preview next quiz:

What is the best treatment option for a 49-year-old woman who is chemotherapy naïve and was recently diagnosed with extensive-stage small cell lung cancer?

A. Carboplatin, pemetrexed, plus pembrolizumab

B. Cisplatin plus gemcitabine

C. Carboplatin plus paclitaxel

D. Cisplatin plus etoposide